Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Haloperidol

FDA-approved product (tablet, oral), marketed as Haldol, Haldol Solutab, Haloperidol and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Haloperidol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tics
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Butyrophenone derivatives
FDA pharmacologic class
Typical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Haloperidol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Haloperidol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Delirium Prevention in Critically Ill Patients

    NCT01187667 · start 2010-08

    Registered record
    Registry ID
    NCT01187667
    Conditions
    Delirium
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-10
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

    NCT01152697 · start 2010-06

    Registered record
    Registry ID
    NCT01152697
    Conditions
    Patient Noncompliance
    Interventions
    haloperidol decanoate; haloperidol; Customized Adherence Enhancement
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatient Noncompliance
    Interventionhaloperidol decanoate; haloperidol; Customized Adherence Enhancement
    PhaseNot applicable
    Registry statusCompleted

  • Dexmedetomidine for the Treatment of Delirium After Heart Surgery

    NCT01140529 · start 2010-05

    Registered record
    Registry ID
    NCT01140529
    Conditions
    Postoperative; Delirium; Psychomotor; Confusion
    Interventions
    Dexmedetomidine; Haloperidol; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-05
    Completion
    2012-06
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative; Delirium; Psychomotor; Confusion
    InterventionDexmedetomidine; Haloperidol; Saline
    PhasePhase 3
    Registry statusTerminated

  • Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis

    NCT01939093 · start 2010-03

    Registered record
    Registry ID
    NCT01939093
    Conditions
    Methamphetamine-induced Psychosis
    Interventions
    Diazepam; Vitamin B1-6-12; Stugeron
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethamphetamine-induced Psychosis
    InterventionDiazepam; Vitamin B1-6-12; Stugeron
    PhasePhase 4
    Registry statusCompleted

  • Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

    NCT01083537 · start 2010-02

    Registered record
    Registry ID
    NCT01083537
    Conditions
    Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Bowel Obstruction
    Interventions
    Cisplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2012-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Bowel Obstruction
    InterventionCisplatin; Paclitaxel
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

    NCT01231074 · start 2010-02

    Registered record
    Registry ID
    NCT01231074
    Conditions
    Obesity; Weight Gain; Psychotropic Induced Weight Gain
    Interventions
    Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Weight Gain; Psychotropic Induced Weight Gain
    InterventionMetformin
    PhasePhase 1
    Registry statusCompleted

  • A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

    NCT00954603 · start 2009-06

    Registered record
    Registry ID
    NCT00954603
    Conditions
    Delirium
    Interventions
    quetiapine; haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2012-07
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium
    Interventionquetiapine; haloperidol
    PhasePhase 3
    Registry statusTerminated

  • Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia

    NCT00838032 · start 2008-08

    Registered record
    Registry ID
    NCT00838032
    Conditions
    Acute Schizophrenia
    Interventions
    Quetiapine fumarate; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-08
    Completion
    2010-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Schizophrenia
    InterventionQuetiapine fumarate; Haloperidol
    PhasePhase 4
    Registry statusUnknown

  • A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia

    NCT00642369 · start 2008-03

    Registered record
    Registry ID
    NCT00642369
    Conditions
    Schizophrenia
    Interventions
    quetiapine fumarate; haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionquetiapine fumarate; haloperidol
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

    NCT00395915 · start 2006-09

    Registered record
    Registry ID
    NCT00395915
    Conditions
    Schizophrenia
    Interventions
    aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-09
    Completion
    2009-12
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionaripiprazole
    PhasePhase 4
    Registry statusUnknown

  • Metabolic Profile and Anthropometric Changes in Schizophrenia

    NCT00534183 · start 2006-06

    Registered record
    Registry ID
    NCT00534183
    Conditions
    Metabolic Syndrome; Diabetes; Obesity
    Interventions
    Olanzapine; Risperidone; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2006-12
    Enrolment
    2,006

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Diabetes; Obesity
    InterventionOlanzapine; Risperidone; Haloperidol
    PhaseNot applicable
    Registry statusCompleted

  • Pilot Study of Haloperidol to Treat Critical Illness Delirium

    NCT00429676 · start 2005-12

    Registered record
    Registry ID
    NCT00429676
    Conditions
    Delirium; Critical Illness
    Interventions
    Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-12
    Completion
    2007-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Critical Illness
    InterventionHaloperidol
    PhasePhase 2
    Registry statusCompleted

  • Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)

    NCT00156065 · start 2005-09

    Registered record
    Registry ID
    NCT00156065
    Conditions
    Schizophrenia
    Interventions
    Haloperidol; Asenapine; Asenapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-10
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionHaloperidol; Asenapine; Asenapine
    PhasePhase 3
    Registry statusCompleted

  • Rapid Tranquillization Trial: TREC-India II

    NCT00455234 · start 2005-09

    Registered record
    Registry ID
    NCT00455234
    Conditions
    Psychotic Disorders; Aggression
    Interventions
    Intramuscular Olanzepine 10 mg; Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Aggression
    InterventionIntramuscular Olanzepine 10 mg; Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg
    PhasePhase 3
    Registry statusCompleted

  • Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

    NCT00625014 · start 2005-03

    Registered record
    Registry ID
    NCT00625014
    Conditions
    Insulin Resistance; Dyslipidemia
    Interventions
    Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-03
    Completion
    2005-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsulin Resistance; Dyslipidemia
    InterventionHaloperidol
    PhaseNot applicable
    Registry statusCompleted